Device maker Vascular Solutions (NSDQ:VASC) reported records sales for its 4th quarter, getting a major Wall Street boost on stronger-than-expected financial results.
vascularsolutions
Ban to stand on Boston Scientific’s Guidezilla catheter
Vascular Solutions claims a win against Boston Scientific
Vascular Solutions signs ‘cooperation agreement’ to get ITGI’s stent on the U.S. market
Vascular Solutions gains on Q3 earnings
Vascular Solutions (NSDQ:VASC) exceeded Wall Street’s expectations with its 3rd-quarter earnings, sending share prices up today.
Vascular Solutions settles Terumo patent infringement beef for $812k
Boston Scientific legal update: Guidant, Guidezilla and ongoing arguments
Medical device giant Boston Scientific (NYSE:BSX) listed no fewer than a dozen legal battles in its latest financial report, notching some wins, some losses and some seemingly circuitous fights without end.
Vascular Solutions legal updates: We’re ready to fight, CEO says
New Jersey medical device maker Vascular Solutions (NSDQ:VASC) has been fighting patent infringement battles on a couple of fronts, and the company is ready to go the distance to protect its portfolio.
Vascular Solutions posts profits, boosts guidance estimates
Vascular Solutions‘ (NSDQ:VASC) Q2 earnings landed exactly within analyst expectations, ending the company’s long streak of beating the Street.
Despite driving profits up almost 20% and boosting guidance estimates to reflect healthy revenue, Wall Street responded by sending share prices down 0.7% by the end of the day.
Boston Scientific’s next-gen imaging catheter lands regulatory wins in 3 major markets
Boston Scientific (NYSE:BSX) landed regulatory wins in 3 major global markets for its OptiCross coronary imaging catheter, which the medical device giant touts as a higher-resolution device for tricky heart procedures.